MNPR Similar Chart Price Prediction
The price of MNPR is predicted to go up -7.53%, based on the high correlation periods with GSBC. The similarity of these two price pattern on the periods is 97.67%.
MNPR
GSBC
Down: -7.53%Similarity: 97.67%
MNPR Revenue Forecast
MNPR EPS Forecast
MNPR FAQs
What is bull’s view on MNPR?
What is bear's view on MNPR?
What is MNPR eps forecast for next quarter？
MNPR Analyst's Forecast
Christopher Raymond
Piper Sandler
Buy
2025-01-10
Price Target
$72
Upside
+184.02%
Piper Sandler initiated coverage of Monopar Therapeutics with an Overweight rating and $72 price target. The firm thinks Monopar's two distinct therapeutic pursuits represent value potential far exceeding the company's current market cap. While these two programs - radiotherapeutics utilizing a unique new oncology target and a small molecule copper mobilizer with "impressive" proof of concept data in Wilson disease - "are quite disparate," they collectively represent meaningful upside to current levels, the analyst tells investors in a research note.
Elemer Piros
Rodman & Renshaw
Strong Buy
2024-10-11
Price Target
$50
Upside
+809.09%
